Each of our technologies are in the clinic, each with its own live clinical program, and each with opportunities beyond current programs
Midatech is a forerunner in the science and development of drug delivery technologies providing a source of therapies for patients suffering from rare diseases with limited treatment options.
Midatech has established a strong and differentiated pipeline and are delivering in our strategy to develop franchises in oncology and immunotherapy, based on our state-of-the-art drug delivery technologies to generate improved as well as new medicines for rare and serious cancers.
The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The Q-Sphera™ sustained release technology platform, with numerous and distinct advantages over traditional polymer microsphere production, utilizes precisely and consistently manufactured monodispersed micro particles such that active drug compounds are released into the body in a tightly controlled manner over an extended period of time (e.g., weeks to months) The MidaCore™ gold nanoparticle technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use. They are composed of a core of gold atoms surrounded by a layer of carbohydrates and linkers for attachment of small molecules (e.g., chemotherapeutics, peptides, etc.) and targeting agents. The small size and multivalency arrangement around the gold core underpin the ability to improve biodistribution and thus safety and efficacy of existing drugs. Midatech’s MidaSolve technology is utilized for potent small molecule chemotherapeutics that have minimal solubility at biological pH, which limits them to oral administration. When reformulated with the MidaSolve technology, the complexed molecules solubilize such that parenteral routes of administration can be employed. This enables local administration directly into the tumour.